Clinical Trial Update: In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating intratumoral Flt3L plus Poly-ICLC with low-dose radiotherapy as an in situ vaccine for low-grade B-cell lymphoma; the study is comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade B-cell Lymphoma

Drugs mentioned

• Flt3L (FLT3 ligand)
• Poly-ICLC (poly-ICLC)

Snippet

Sponsor: Joshua Brody | Conditions: Low-Grade B-cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED